CBL-B Inhibitor NX-1607

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, small-molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulatory and antineoplastic activities. Upon oral administration, CBL-B inhibitor NX-1607 targets, binds to and inhibits the activity of CBL-B, which may result in immune activation, the infiltration of natural killer (NK) cells and activated CD8+ T-cells in the tumor microenvironment (TME), and the inhibition of tumor growth. CBL-B, an E3 ubiquitin ligase expressed in all leukocyte subsets including T-cells and NK cells, is a negative regulator of immune activation.

**Synonyms:** - Casitas B-lineage Lymphoma B Inhibitor NX-1607 - Casitas B-lineage Lymphoma Proto-oncogene-b Inhibitor NX-1607 - NX 1607 - NX-1607 - NX1607